Invitation by Roger Paredes, MD, PhD | European Meeting on HIV & Hepatitis 2021
Dr. Roger Paredes from IrsiCaixa AIDS Research Institute will give his lecture Update on Therapeutics Options at the European Meeting on HIV & Hepatitis 2021 on 26 – 28 May 2021.
Learn more about the program: https://bit.ly/3yqskAS
For direct registration: https://bit.ly/3fuoRc6
Join this meeting to receive the latest clinical recommendations from world-leading experts. Explore abstract-driven presentations, and dive into truly global round table discussions.
PROGRAM
26 May 2021
Session 1: SARS-CoV-2 Variants
Session 2: Clinical Management of COVID Patients
Session 3: Impact of COVID-19 Pandemic on People Living with HIV
Abstract - Driven Presentations I
Andrea De Luca Lecture
27 May 2021
Session 4: Long-acting ARVs
Session 5: Clinical Management of Hepatitis
Guided Poster Tour
28 May 2021
Session 6: Presentations from the Industry
Session 7: Genetic Variations
Abstract - Driven Presentations
Special Lecture
Founded nineteen years ago as the European HIV Resistance Workshop, the European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance has evolved to embrace all aspects of the clinical care of people living with HIV in Europe. Particular emphasis is put on optimal treatment strategies, clinical virology, molecular epidemiology, and public health aspects of HIV, HBV, HCV, and emerging viruses throughout Europe.
Visit https://bit.ly/3yqskAS to discover more HIV & Hepatitis related meetings & enduring materials.
For more medical education programs, as well as the latest scientific information, visit https://academicmedicaleducation.com/
Видео Invitation by Roger Paredes, MD, PhD | European Meeting on HIV & Hepatitis 2021 канала Academic Medical Education
Learn more about the program: https://bit.ly/3yqskAS
For direct registration: https://bit.ly/3fuoRc6
Join this meeting to receive the latest clinical recommendations from world-leading experts. Explore abstract-driven presentations, and dive into truly global round table discussions.
PROGRAM
26 May 2021
Session 1: SARS-CoV-2 Variants
Session 2: Clinical Management of COVID Patients
Session 3: Impact of COVID-19 Pandemic on People Living with HIV
Abstract - Driven Presentations I
Andrea De Luca Lecture
27 May 2021
Session 4: Long-acting ARVs
Session 5: Clinical Management of Hepatitis
Guided Poster Tour
28 May 2021
Session 6: Presentations from the Industry
Session 7: Genetic Variations
Abstract - Driven Presentations
Special Lecture
Founded nineteen years ago as the European HIV Resistance Workshop, the European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance has evolved to embrace all aspects of the clinical care of people living with HIV in Europe. Particular emphasis is put on optimal treatment strategies, clinical virology, molecular epidemiology, and public health aspects of HIV, HBV, HCV, and emerging viruses throughout Europe.
Visit https://bit.ly/3yqskAS to discover more HIV & Hepatitis related meetings & enduring materials.
For more medical education programs, as well as the latest scientific information, visit https://academicmedicaleducation.com/
Видео Invitation by Roger Paredes, MD, PhD | European Meeting on HIV & Hepatitis 2021 канала Academic Medical Education
Показать
Комментарии отсутствуют
Информация о видео
12 мая 2021 г. 19:18:03
00:00:39
Другие видео канала
![Preview: Highlights International Workshop on HIV & Women 2021 | Sharon Walmsley, FRCPC, MD, MSC](https://i.ytimg.com/vi/R2YdYyFG4V4/default.jpg)
![A new model for early clinical development of TB drugs and its application... | Norbert Heinrich, MD](https://i.ytimg.com/vi/qFEmqKQZCwU/default.jpg)
![Clinical Considerations of Aging People Living with HIV - Marta Boffito](https://i.ytimg.com/vi/E1EWCXiQ0us/default.jpg)
![The ABC of viral hepatitis | Mark Thursz, MRCP](https://i.ytimg.com/vi/CouyxcDBHRE/default.jpg)
![Updates on WHO HIV Treatment Guidelines - Fujie Zhang, MD, PhD](https://i.ytimg.com/vi/Xyr58KfwWSc/default.jpg)
![Is HCV drug resistance an issue? | Jürgen Rockstroh, MD](https://i.ytimg.com/vi/eMJtOA164uY/default.jpg)
![Is NAFLD/NASH a Public Health Challenge in 2022? - Zobair M. Younossi, MD, MPH, FACG, FACP, AGAF](https://i.ytimg.com/vi/T-U4xYQNp_E/default.jpg)
![Antiretroviral Therapy in Pregnant Women with HIV and Neonates - Lijun Sun](https://i.ytimg.com/vi/UyvA6qjkIwU/default.jpg)
![Long Acting Antivirals for Treatment and Prevention | Martin Markowitz, MD](https://i.ytimg.com/vi/jtTBnIX504w/default.jpg)
![Exercise and aging | Wendy Kohrt, PhD](https://i.ytimg.com/vi/bkVgsTpWIr8/default.jpg)
![Symposium 1: ViiV - What’s New in HIV Treatment & Prevention for Youth? - Panel Discussion](https://i.ytimg.com/vi/FfUrMmnTJag/default.jpg)
![Invitation to join the HIV Prevention Review Meeting 2022 - 30-31 March](https://i.ytimg.com/vi/Xs4wfVPuazY/default.jpg)
![Case-Based Discussion of Oral Antivirals for COVID-19: Part 1 - Catia Marzolini, PharmD, PhD](https://i.ytimg.com/vi/AffRMzV0p_g/default.jpg)
![Anti-HBV potential of PD-1/PD-L1 blockade in chronic HBV infection | Daniel Verdon](https://i.ytimg.com/vi/kX9-cazXCVU/default.jpg)
![Research into Aging with HIV: Lessons Learned and Outstanding Challenges - Peter Reiss](https://i.ytimg.com/vi/IZ7CCP7pGE0/default.jpg)
![State of the Art Interventions in Improving Pediatric HIV Outcomes in OVC Programs - Grace Mayanja](https://i.ytimg.com/vi/B7JMeVkVOLs/default.jpg)
![Using Infant Animal Models to Advance Pediatric HIV Prevention, Vaccines .. | Ann Chahroudi, MD, PhD](https://i.ytimg.com/vi/0DnE_AJXX84/default.jpg)
![Differentiated & Simplified PrEP for HIV Prevention | Heather-Marie Schmidt, BMedSc (Hon), MPH, PhD](https://i.ytimg.com/vi/b1AmSpMLRQA/default.jpg)
![Acute hepatitis A to E, diagnosis and management | Thomas Berg, MD](https://i.ytimg.com/vi/jWQMtxvHUGg/default.jpg)
![Does resistance still matter? | Daniel Kuritzkes, MD](https://i.ytimg.com/vi/l-igc489l0E/default.jpg)